Drug Profile


Alternative Names: Anti-PD-L1 monoclonal antibody; Anti-PD-LI mAb; Anti-programmed cell death 1 ligand 1 monoclonal antibody; Imfinzi; MEDI-4736

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MedImmune
  • Developer Advaxis; AstraZeneca; Canadian Cancer Trials Group; Case Comprehensive Cancer Center; Celgene International SARL; Centre Leon Berard; Childrens Hospital Los Angeles; Eli Lilly; Fondazione IRCCS Istituto Nazionale dei Tumori; GlaxoSmithKline; Gradalis; Grand Hopital de Charleroi; Grupo Espanol de Tumores Neuroendocrinos; Gustave Roussy; Immunocore; Institut Claudius Regaud; Juno Therapeutics; Kyoto Breast Cancer Research Network; Ludwig Institute for Cancer Research; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; Mirati Therapeutics; National Cancer Institute (USA); National Health and Medical Research Council; Northwestern University; Pharmacyclics; Plexxikon; Samsung Medical Center; Seoul National University Hospital; Swiss Group for Clinical Cancer Research; University of Maryland Greenbaum Cancer Center; University of Texas M. D. Anderson Cancer Center; VentiRx Pharmaceuticals; Washington University School of Medicine; Yale University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Urogenital cancer
  • Phase III Head and neck cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
  • Phase II/III Breast cancer; Pancreatic cancer
  • Phase II Acute myeloid leukaemia; Biliary cancer; Brain metastases; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Glioblastoma; Hepatocellular carcinoma; Mesothelioma; Multiple myeloma; Myelodysplastic syndromes; Neuroendocrine tumours; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Sarcoma
  • Phase I/II Cervical cancer; Chronic lymphocytic leukaemia; Cutaneous T cell lymphoma; Lung cancer; Lymphoma; Malignant melanoma; Peripheral T-cell lymphoma; Soft tissue sarcoma
  • Phase I CNS cancer; Lymphoproliferative disorders; Myelofibrosis; Non-Hodgkin's lymphoma; Renal cell carcinoma; Thyroid cancer

Most Recent Events

  • 03 Aug 2017 University Medical Center Groningen and AstraZeneca plan a phase I trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in Netherlands (NTR6553)
  • 02 Aug 2017 University Hospital Inselspital and AstraZeneca plans a phase II NITIMIB trial for Bladder cancer (Combination therapy, Neoadjuvant therapy, Second-line therapy) (NCT03234153)
  • 31 Jul 2017 Durvalumab receives Breakthrough Therapy status for Non-small cell lung cancer (Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top